Compare Automatic Data Processing Inc (ADP) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

ADP trades at $273.68, up 0.87% today, near its consensus price target of $280.50. The stock shows bullish technical signals with strong moving averages and support at $270. Recent quarterly earnings consistently beat estimates, with Q2 2026 EPS of $2.64 surpassing the $2.59 forecast. Revenue growth is steady, reaching $20.56 billion in 2025, with a net income margin of 20.11% and robust ROE of 72.24%.

Outlook remains positive given earnings momentum and dividend stability, but high valuation multiples (P/E 24.78, P/S 4.98) pose risks if growth slows. Analyst sentiment is mixed with 63.89% hold ratings, reflecting caution amid elevated prices. Key risks include labor market sensitivity and competitive pressures in payroll processing.

Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.

The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.